RxDoctor Payments Data

Benjamin Herms, MD

Hematology & Oncology · Cincinnati, OHNPI 1730218876

Payments from drug & device makers

$66,983in general payments, 2019–2025

Across 63 payments — averaging $1063.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$46K
  • Roche Products Limited$12K
  • AstraZeneca$8K
  • E.r. Squibb & Sons, L.L.C.$133
  • AbbVie$130
  • Novartis$127
  • plus $518 from 12 others

What the payments were for

  • Food & beverage$68972%
  • Education$26528%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$66,983 in reported general payments places this provider in the 65th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$3,011,061
Medicare patients
574
Services billed
118,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib35$556,998
IbrancePalbociclib25$389,101
Lenalidomide26$329,234
TukysaTucatinib11$287,565
CalquenceAcalabrutinib Maleate19$280,822
RevlimidLenalidomide17$273,096
InlytaAxitinib11$226,463
KisqaliRibociclib Succinate12$200,269
Sunitinib Malate14$112,006
EliquisApixaban104$75,160
Imatinib Mesylate41$21,012
XareltoRivaroxaban14$9,787
Fentanyl19$2,357
Oxycodone Hcl112$2,142
Exemestane11$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Inlyta, Eliquis$85$690,724140 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$30$556,99835 claims
AstraZenecaCalquence$8,145$280,82219 claims
NovartisKisqali$127$200,26912 claims
Johnson & JohnsonXarelto$100$9,78714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →